OPTEL Implementation of Mediledger VRS In Progress

As you may know, the “Big 3” pharmaceutical distributors that handle most of the drug distribution in the United States (Cardinal Health, McKesson, and AmerisourceBergen) will not accept non-serialized returned products, also known as saleable returns, after November 27, 2019.

In letters to the pharma industry sent in late 2018, these distributors outlined their expectations and options. To recap:

  • Manufacturers can send aggregated serialized data with each shipment so product identifiers can be verified internally. This scenario requires aggregation and serialized data exchange via EPCIS (1.1, 1.2). Because it can take up to 90 days to successfully complete testing, pharma organizations are encouraged to begin the process several months before the target date.
  • The second scenario involves a Verification Router Service (VRS), in which manufacturers maintain their own database of serial numbers and subscribe to a third-party routing service that manages all requests for verification as well as the responses from the manufacturer.

To ensure that our customers meet the Big 3’s expectations by the November deadline, OPTEL is in the process of implementing Chronicled’s cloud-based VRS called MediLedger. During this initial phase of the process, we are installing and configuring the system, connecting to some of our customers’ repositories and confirming that our verifications work properly. We expect to complete the testing this summer and will roll out MediLedger to all our North American customers so the VRS is fully configured and functional by Q3 2019.

We believe that the MediLedger solution, which is powered by blockchain, is the best possible option for our customers.

There is an established, built-in connection to the Big 3 wholesale distributors, which will facilitate a seamless transmission of verification requests. Because the MediLedger system is architected to transmit the most relevant information about serialized pharmaceutical products, it will also be easier to implement from a technical perspective. Importantly, our customers won’t have to do anything special for the system to work properly. In short, we expect the MediLedger option will deliver a relatively seamless means to meet the DSCSA saleable returns requirements.

Our team of dedicated, international technical consultants are available to resolve any issues quickly, offering 24/7 technical support through our personalized service-level agreement (SLA) offer, with optional Virtual Tech Support. In addition, we are offering a transparent, tiered pricing structure that includes a one-time implementation fee and a monthly charge based on the number of transactions you conduct; the more transactions you have, the lower your cost per verification will be.

If you have any questions about VRS or MediLedger, please contact us.